Sameer A. Parikh

Toyota Motor Corporation (Switzerland) — Switzerland

Medicine · Health Sciences

46h-index8.5kcitations439works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(304), Lymphoma Diagnosis and Treatment(145), Immunodeficiency and Autoimmune Disorders(78), CAR-T cell therapy research(70), Phagocytosis and Immune Regulation(41)

Publications439 total

Supplementary Table S1 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figure Legends from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Figures from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Supplementary Table S2 from AXL Inhibition Improves the Antitumor Activity of Chimeric Antigen Receptor T Cells
2025Open Access
Genomic profiling reveals molecular heterogeneity in patients with Richter transformation (RT) and chronic lymphocytic leukemia (CLL)
Leukemia Research·2025Open Access
CHIP amplifies the risk of lymphoid malignancies in individuals with monoclonal B-cell lymphocytosis (MBL)
Blood Cancer Journal·2025Open Access
The predictive value of mosaic chromosomal alterations for lymphoid malignancies varies by monoclonal B-cell lymphocytosis status
Blood·2025
Ibrutinib enhances 41BB-costimulated CART19 function and persistence through immune reprogramming: Insights from the phase 3 ECOG-ACRIN E1912 clinical Trial
Blood·2025Open Access
IL-4 epigenetically reprograms CART19-28ζ cells to drive dysfunction
Blood·2025Open Access
Venetoclax-obinutuzumab in frontline and R/R CLL: Outcomes compared to age- and sex-matched general population
Blood·2025
Genetic analysis of B and T cell subsets from CLL patients prior to and at Richter's transformation
Blood·2025Open Access
Progression of disease within 36 months (POD36) of starting first-line targeted therapy independently predicts poor overall survival in patients with chronic lymphocytic leukemia (CLL)
Blood·2025
Genomic profiling in CLL patients after BTK inhibitor progression identifies enrichment of mutations in MAPK pathway and epigenetic regulators
Blood·2025Open Access
Pirtobrutinib versus usual care for patients with richter transformation of chronic lymphocytic leukemia: Inverse probability of treatment weighting-based analysis of BRUIN trial and mayo observational cohort
Blood·2025Open Access
Non-CLL-type MBL and chip are associated precursor conditions: Insights from Mayo Clinic's MBL screening cohort
Blood·2025Open Access
Other cancers in patients with chronic lymphocytic leukemia/SMALL lymphocytic lymphoma
Blood·2025Open Access
Characteristics and prognostic factors in adult hemophagocytic lymphohistiocytosis: A large single-institution analysis
Blood·2025Open Access
COVID-19 convalescent plasma for B-cell depleted patients: a systematic review and individual patient data meta-analysis
Frontiers in Medicine·2025Open Access
Expert consensus opinion on the management of hairy cell leukemia in elderly patients
Leukemia & lymphoma/Leukemia and lymphoma·2025
Treatment patterns for del(17P)/mutated <i>TP53</i> or relapsed/refractory (R/R) CLL among experts and lower-volume treaters.
JCO Oncology Practice·2025
page 1 of 22Next →

Frequent Co-authors

Tait D. Shanafelt(22), Neil E. Kay(22), Wei Ding(19), Timothy G. Call(18), José F. Leis(14), Susan L. Slager(14), Susan M. Schwager(13), Asher Chanan‐Khan(9), Curtis A. Hanson(9), Kari G. Chaffee(9), Kari G. Rabe(8), Saad S. Kenderian(8), Eli Muchtar(7), Jennifer A. Woyach(5), Kerry A. Rogers(5), Jennifer R. Brown(5), Gerard Lozanski(5), James S. Blachly(5), Thomas M. Habermann(5), Amber B. Koehler(5)